Dabur India shares are set to be in focus after the US FDA issued an import alert on drugs manufactured at its Silvassa plant, citing data integrity lapses. The company said the impact is limited to a small portion of operations, while broader business and domestic sales remain unaffected.
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.